I am a Professor and Chair of the Department of Pharmacology at UTHSCSA. My research focus, initiated at the University of Pennsylvania, has been centered on the mechanisms of action of antidepressants and I have also carried out clinical studies with psychiatric colleagues on both the biology of depression and the onset of action of antidepressants. My research has long had a systems emphasis measuring neurochemical effects of antidepressants in brain and associated behavioral actions. Such studies initially focused on noradrenergic and serotonergic systems but more recently has emphasized neurotrophin signaling also. Our studies progressed to using techniques such as quantitative autoradiography, immunohistochemistry and in vivo voltammetry to measure effects in specific brain structures contained within areas of brain, such as hippocampus, medial prefrontal cortex and amygdala, known to be involved in the regulation of mood. And more recently we have used newly developed techniques such as optogenetics and DREADDS to examine specific brain circuits involved in the behavioral effects of the novel antidepressant, ketamine, as well as novel drugs that mimic the effects of ketamine without having their adverse effect profile.
My research has been funded almost continually by either NIH or the VA for over 40 years and I have received research funds from pharmaceutical companies to study potential antidepressants that they were developing. Our studies have generated over 150 original research reports and almost 60 book chapters and reviews and I have co-edited and contributed to three books. I have been a Career Scientist of the VA and received a MERIT Award from NIH. I have trained numerous graduate students and postdoctoral fellows and several research-track fellows. Many have achieved prominence in either academic or industry positions, including three Chairs of departments and a Dean of a College of Pharmacy. In addition, I have supervised primarily summer research projects for many undergraduates including underrepresented minorities (URMs). I was the Director of an NIH-funded R25 grant aimed at attracting undergraduate URMs into doctoral programs in the neurosciences. I have held various positions of prominence in national and international scientific colleges. For many years, I was the Secretary of the American College of Neuropsychopharmacology (ACNP) and was its President. I was a Councilor of the International College of Neuropsychopharmacology (CINP) and currently serve as the editor-in-chief of its official publication, the International Journal of Neuropsychopharmacology.For many years, I have been a member of the Scientific Council of the Brain Behavior Research Foundation (formerly called NARSAD).
All Sessions by Alan Frazer
Thursday 3 October
Meet the Expert: 60 years of antidepressants - where are we now?
10:30 - 12:00
Chair: Georgia Salanti, Universität Bern, Switzerland and Ioannis Michopoulos, National and Kapodistrian University of Athens, Greece
Speaker: Alan Frazer, UT Health San Antonio, USA
Meet the Expert
CINP2019 is a 2.5-day international meeting that will feature plenaries, meet the expert sessions, satellite symposia as well as interactive educational workshops.
Keep up to date with Conference News & Alerts. Sign Up
International Conference Services GmbH
Gonzagagasse 17, 1010 Vienna, Austria